Aurovitas

What Aurovitas does

Aurovitas Spain S.A.U. is a Madrid-based pharmaceutical company that develops, manufactures, and commercializes generic medications through direct sales channels in Spain. Founded in 2014 as the Spanish subsidiary of India's Aurobindo Pharma Limited, the company operates within a vertically integrated global group that controls the full pharmaceutical value chain from active pharmaceutical ingredient (API) synthesis through finished dosage form manufacturing. The group's manufacturing footprint spans 29 production plants across India (19), the United States (3), Europe (2), and Brazil (1), supported by seven research and development centers and regulatory approvals from the EMA, US FDA, UK MHRA, and Brazil's ANVISA.

The company's product portfolio covers generic medications, branded generics, over-the-counter products, and biosimilars across key therapeutic areas including antineoplastics (oncology), central nervous system, cardiovascular, and digestive therapies. Through a dedicated direct sales force, Aurovitas reaches more than 5,000 community pharmacies across Spain and supplies major Spanish hospitals, holding a Top 10 position in the Spanish pharmaceutical market and a Top 7 ranking in the hospital segment with particular strength in oncology and anti-infectives. The company also supplies APIs and finished dosage forms to other pharmaceutical companies globally as part of the parent group's contract manufacturing and B2B activities.

Revenue is generated through one-time sales of generic prescriptions, branded generics, OTC products, and APIs under standard pharmaceutical distribution models with margins and reimbursement governed by Spain's national healthcare system. The parent group's revenues exceed €3 billion annually across 150 countries with a workforce of more than 20,000 employees globally. Distribution operates through three primary channels: direct field sales to community pharmacies, a specialized hospital sales team for institutional procurement, and centralized customer service for pharmacy and hospital orders via phone, email, and dedicated digital ordering. No direct-to-consumer e-commerce channel is operated, and no pricing is publicly disclosed.

Name

Aurovitas

Legal name

Aurovitas Spain S.A.U.

Website

https://aurovitas.es

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

51–100 employees

Short description

Aurovitas Spain S.A.U. commercializes generic, branded, and OTC pharmaceuticals through direct sales to over 5,000 pharmacies and major hospitals in Spain. The Madrid-based subsidiary is part of India's Aurobindo Pharma Group, a vertically integrated generics manufacturer with €3 billion global turnover and operations in 150 countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Generic pharmaceuticals
• Active pharmaceutical ingredients
• Biosimilar development
• Hospital medication supply
• Pharmaceutical manufacturing

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Medications: Commercialization of generic pharmaceutical products covering all key therapeutic areas including antineoplastics, CNS, cardiovascular, and digestive medications
2. Branded Medications: Sale of branded pharmaceutical products to pharmacies and hospitals in Spain
3. OTC Products: Over-the-counter products including weight management solutions like Beacita distributed through pharmacies
4. API Manufacturing: Active Pharmaceutical Ingredient manufacturing for internal use and supply to other pharmaceutical companies globally

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Aurovitas develops, manufactures, and commercializes generic pharmaceutical products, including branded generics, OTC medications, injectables, and Active Pharmaceutical Ingredients, serving pharmacies and hospitals in Spain. The portfolio spans key therapeutic areas such as antineoplastics, central nervous system, cardiovascular, and digestive medications, with an emerging biosimilars pipeline. Products are delivered through a direct sales force and centralized customer service to community pharmacies and major hospitals across Spain.

Product overview

Aurovitas is a pharmaceutical group focused exclusively on the development, manufacturing, and commercialization of generic medications. The company operates a vertically integrated model, controlling the entire value chain from API production through finished dosage form manufacturing to commercialization. The product portfolio includes branded generics, unbranded generic medications, OTC products, and biosimilars. Key therapeutic areas covered include Antineoplastics (oncology), Central Nervous System, Cardiovascular, and Digestive. Products are distributed through two primary channels: pharmacy (Vademécum Farmacias) and hospital (Vademécum Hospitales). The group is expanding into biosimilars through its parent company Aurobindo's development program. The Spanish subsidiary serves over 5,000 pharmacies directly and major hospitals, positioning the group in the Top 10 of national laboratories.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Medications Portfolio A broad portfolio of generic medications including branded generics, generic drugs, and OTC products covering key therapeutic areas such as Antineoplastics (oncology), Central Nervous System, Cardiovascular, and Digestive; commercialized through Spanish pharmacies and hospitals.
• Vademécum Farmacias
• Vademécum Hospitales
• Active Pharmaceutical Ingredients (API)
• Beacita
• Biosimilars Portfolio Biosimilar medications developed through the Aurobindo Group, starting with bevacizumab (monoclonal antibody for cancer treatment) and expanding to a portfolio of eight biosimilar products.
• Injectable Medications

Quantifiable outcome

• Reach over 5,000 pharmacies directly in Spain with Top 10 national market position
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Fundación EstudiantesminorGTM or Marketing Partner · 1 March 2018Sponsorship of the basketball club's inclusive academy 'Pozuelo Encesta con el Estu' supporting players with intellectual disabilities. Includes advertising presence at Liga Endesa games at WiZink Center, hospitality access, and participation in Club de Negocios Movistar Estudiantes.
• TL Biopharmaceutical AGcoreStrategic or Co-development Partner · 1 February 2017Licensing agreement for four biosimilar products acquired from Swiss company TL Biopharmaceutical AG, marking Aurovitas/Aurobindo's entry into biosimilar development. Initial product is bevacizumab (anticancer monoclonal antibody), with plans for eight additional biosimilar products. Development supported by dedicated manufacturing facility in India.

Scale indicators10 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Apotex: Canadian-headquartered global generic pharmaceutical manufacturer with presence in Europe and broad therapeutic coverage. Comparable vertically integrated model and competing for hospital tenders in similar categories.
• Teva Pharmaceutical Industries: World's largest generic medicines manufacturer with deep European and US presence, broad therapeutic coverage, and parallel biosimilar development. Directly comparable to Aurovitas' pan-European commercial model and vertical integration.
• Kern Pharma: Leading Spanish generic pharmaceutical manufacturer headquartered near Barcelona, with a comparable portfolio across therapeutic areas and direct pharmacy/hospital sales overlap in Spain.
• Viatris: Formed from the Mylan-Upjohn merger; one of the largest global generic players with a comparable product breadth across therapeutic areas, strong European commercial footprint, and established biosimilar ambitions.
• Stada Arzneimittel: Privately-held European generics leader headquartered in Germany with significant Spain presence. Comparable mid-sized integrated generics model with hospital and pharmacy channels overlapping with Aurovitas'.
• Krka: Slovenian-headquartered generic pharmaceutical company with vertically integrated API-to-finished-product manufacturing and pan-European commercial reach, including established Spain and Portugal operations.
• Accord Healthcare: European generics arm of India's Intas Pharmaceuticals, with parallel model of parent-led API integration and European commercial expansion. Directly comparable scale, therapeutic coverage, and channel mix to Aurovitas.
• Cinfa: Major Spanish pharmaceutical company with a strong generics and OTC portfolio, distributing through Spanish pharmacies and hospitals. Direct overlap with Aurovitas' Vademécum Farmacias and Beacita-style OTC offerings.
• Sandoz: Global generic and biosimilar pharmaceutical company, spun out of Novartis. Closest direct peer to Aurovitas in scale, vertical integration, and biosimilar pipeline (Omjiaro, Hyrimoz, Erelzi) across all major European and US markets.
• Zentiva: European-focused generic pharmaceutical company with strong Central and Western Europe presence, including Spain. Similar pan-European commercial model and broad therapeutic area coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurovitas